ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO742

Intradialytic Blood Pressure Stability during Hemodialysis with a Novel Hemodialysis Device

Session Information

Category: Dialysis

  • 601 Standard Hemodialysis for ESRD


  • Alvarez, Luis, Palo Alto Medeical Foundation, Palo Alto, California, United States
  • Chen, Paul, Outset Medical, San Jose, California, United States
  • Hu, Dean, Outset Medical, San Jose, California, United States
  • Prichard, Sarah S., Ouset Medical Inc, San Jose, California, United States

Intradialytic hypotension (IDH) is a common event. The literature suggests that up to 20% of dialysis patients have IDH that requires intervention, over 70% of patients have a decrease of systolic BP (SBP) of 20mmHg and up to 27% have a decrease of of 40mmHg. Patients with frequent IDH have worse outcomes. The Tablo™ Hemodialysis System is a novel technology designed to be simple for both patients and staff to use, which enables self-care hemodialysis in a variety of clinical settings. This study reports on the intradialytic BP of patients dialyzed using Tablo.


2012 dialysis treatments using Tablo were assessed in the outpatient setting at 10 dialysis units. Tablo automatically takes and records BP at preset intervals during dialysis as prescribed by the physician and transmits them wirelessly in real time. The percent of patients with a change in SBP of 20 mmHg or 40mmHg, a change in mean arterial pressure of 10mmHg, or a SPB < 90mmHg (with a diastolic BP of <60) were calculated. UF and pre/post weights were also collected.


Results are shown in Table 1


Patients dialyzed with Tablo have less IDH compared to that reported in the literature. The reason for this difference may relate to differences in the patient populations or unique features of Tablo. This important clinical observation needs further study to determine if the use of Tablo could favorably influence outcomes.

Table 1
Sample size (n)2012
Δ Systolic BP > 20mmHg765(30%)
Δ Systolic BP > 40mmHg0 (0%)
Δ MAP > 10mmHg919 (45.6%)
< 90 Sys BP & < 60 Dia BP130 (6.5%)
Pre-dialysis weight81.2 + 20.8 kg (45.1-147.2kg)
Post-dialysis weight78.5 + 20.6 kg (41.0-145.2kg)
Avg ultrafiltration2486 + 1094 mL (0-6000ml)
Avg UF rate 8.7 + 3.7 mL/kg/h (0-25.2 ml/kg/hr)


  • Commercial Support